DeepDx Prostate

Deep Bio is a Seoul-based digital pathology AI company focused on cancer diagnostics. It helps pathologists cope with growing biopsy volumes and the variability of manual Gleason grading by applying deep learning to digitized slides.

DeepDx Prostate analyzes H&E-stained prostate needle biopsy slides, detects and localizes cancer, assigns Gleason patterns 3, 4 and 5 with colored overlays, calculates Gleason score and grade group, and measures tumor and tissue length and tumor-to-tissue ratios. Pathologists can edit annotations and metrics update in real time. Variants cover needle biopsy and TURP, alongside DeepDx Breast, DeepDx Viewer and DeepCDx Membrane IHC for biomarker scoring. It runs in the cloud or on premises for hospital pathology departments and laboratories.

• Cancer detection: detects and localizes regions of interest on prostate needle biopsy slides.
• Gleason grading: colored overlays for patterns 3, 4 and 5 plus Gleason score and grade group.
• Quantification: measures tissue and tumor length, pattern percentages and tumor-to-tissue ratio.
• Editable results: annotations can be corrected and metrics recalculate in real time.
• Product family: TURP variant, DeepDx Breast, DeepDx Viewer and DeepCDx Membrane IHC.
• Flexible deployment: available in the cloud or on premises.

Urology and oncology hospitals in Vietnam could use the software to grade prostate biopsies faster and more consistently. Private pathology labs could add AI quality control on cases signed out by junior pathologists. Medical universities could use the tool to train residents in Gleason grading.

Reports 99% sensitivity and 97% specificity for prostate cancer detection on needle biopsies. Analyzes each core in about 30 seconds, with more than 700,000 cores processed. Standardizes Gleason grading and tumor measurement, reducing inter-observer variability. Supports first read, concurrent read, quality control and education, so labs can choose how deeply to rely on it.

Prostate cancer cases are rising in aging Asian populations, while pathologists remain scarce and slide scanners are becoming common in larger hospitals. AI-assisted grading and biomarker scoring are moving from research into routine practice, giving pathology departments in Vietnam and Southeast Asia a way to scale cancer diagnostics.

Deep Bio Inc. is headquartered in Guro-gu, Seoul. DeepDx Prostate is approved by Korea's MFDS and CE marked; the company holds ISO 13485, ISO 27001 and MDSAP certifications. It launched DeepDx Prostate in Switzerland in 2024 and won a CES Innovation Award in 2023. Partners include Roche, PathAI, Visiopharm, Indica Labs, Stanford Medicine and Dana-Farber Cancer Institute.